In the mAb Race, Don’t Stumble at Characterization
Researchers Adapt Existing Techniques to Deal with Challenging New Monoclonal Antibodies
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
For full access to this article login to GEN Select now.
CGH Sheds Its Light on Disease Etiology
Diseases that Have Defied Description Can Now Be Described and Explained
- Array comparative genomic hybridization (CGH) is illuminating DNA copy number variations (CNV) throughout the genome to diagnose disease etiology and to help tailor treatment regimens for patients to improve health outcomes. In January 2007, the College of American Pathologists and American Society of Clinical Oncology (CAP/ASCO) published guideline ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.